Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Acerbi

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Journal of Cardiovascular Pharmacology and Therapeutics|May 16, 2002
Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trialM R Cesarone, L Incandela, M T DeSanctis, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|May 16, 2002
Flight microangiopathy in medium-to-long distance flights: prevention of edema and microcirculation alterations with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, randomized, controlled trialM R Cesarone, G Belcaro, L Incandela, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|February 1, 1993
Intraocular and plasma kinetics of tenoxicam in rabbitsM Del Puppo, M G Kienle, R Ratiglia, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|September 17, 2002
HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trialG Belcaro, M R Cesarone, P Bavera, et al.
Journal of Endocrinological Investigation|December 24, 2005
Undetectable inferior petrosal sinus levels of PTH-related peptide (PTHrP) in patients with ACTH-dependent Cushing's diseaseL Manetti, L Grasso, C Vignali, et al.
Journal of Endocrinological Investigation|February 27, 2003
Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomasP Viacava, M Gasperi, G Acerbi, et al.
Journal of Endocrinological Investigation|January 20, 2006
Peroxisome proliferator-activated receptor (PPAR)gamma is highly expressed in normal human pituitary glandF Bogazzi, D Russo, M T Locci, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|May 16, 2002
HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trialL Incandela, G Belcaro, S Renton, et al.
Angiology|January 29, 2005
HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry studyM R Cesarone, G Belcaro, L Pellegrini, et al.
Angiology|May 17, 2006
Cramps and muscular pain: prevention with pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathyG Vinciguerra, G Belcaro, M R Cesarone, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Cardiovascular Pharmacology and Therapeutics|May 16, 2002
Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trialM R Cesarone, L Incandela, M T DeSanctis, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|May 16, 2002
Flight microangiopathy in medium-to-long distance flights: prevention of edema and microcirculation alterations with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, randomized, controlled trialM R Cesarone, G Belcaro, L Incandela, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|February 1, 1993
Intraocular and plasma kinetics of tenoxicam in rabbitsM Del Puppo, M G Kienle, R Ratiglia, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|September 17, 2002
HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trialG Belcaro, M R Cesarone, P Bavera, et al.
Journal of Endocrinological Investigation|December 24, 2005
Undetectable inferior petrosal sinus levels of PTH-related peptide (PTHrP) in patients with ACTH-dependent Cushing's diseaseL Manetti, L Grasso, C Vignali, et al.
Journal of Endocrinological Investigation|February 27, 2003
Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomasP Viacava, M Gasperi, G Acerbi, et al.
Journal of Endocrinological Investigation|January 20, 2006
Peroxisome proliferator-activated receptor (PPAR)gamma is highly expressed in normal human pituitary glandF Bogazzi, D Russo, M T Locci, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|May 16, 2002
HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trialL Incandela, G Belcaro, S Renton, et al.
Angiology|January 29, 2005
HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry studyM R Cesarone, G Belcaro, L Pellegrini, et al.
Angiology|May 17, 2006
Cramps and muscular pain: prevention with pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathyG Vinciguerra, G Belcaro, M R Cesarone, et al.
Pageof 4